Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 20/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 11/20 | 1.00 |
| ▸ | FAP | Q12884 | 1/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4230400 | 1.00 | DPP4 (1.00) | DPP4KCNH2FAPCYP3A4CHRM1 | |
| SCHEMBL8237500 | 0.93 | DPP4 (0.88) | DPP4KCNH2FAPCYP3A4CHRM1 | |
| SCHEMBL5051652 | 0.91 | DPP4 (1.00) | DPP4KCNH2FAPCHRM1 | |
| SCHEMBL5051649 | 0.91 | DPP4 (1.00) | DPP4KCNH2FAPCHRM1 | |
| Hydrochloric Acid SCHEMBL4220122 | 0.91 | DPP4 (0.99) | DPP4KCNH2FAPCHRM1 | |
| Hydrochloric Acid SCHEMBL4220124 | 0.91 | DPP4 (0.99) | DPP4KCNH2FAPCHRM1 | |
| SCHEMBL4225476 | 0.89 | DPP4 (1.00) | DPP4KCNH2FAPCYP3A4CHRM1 | |
| SCHEMBL4225482 | 0.89 | DPP4 (1.00) | DPP4KCNH2FAPCYP3A4CHRM1 | |
| SCHEMBL8236796 | 0.87 | DPP4 (0.82) | DPP4KCNH2FAP | |
| SCHEMBL8236531 | 0.86 | DPP4 (0.77) | DPP4KCNH2FAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090192138-A1 | COMPOUNDS | BAESCHLIN DANIEL KASPAR | 2009-07-30 | — | — | US | disclosed |
| EP-1966215-A1 | CONDENSED HETEROCYCLIC COMPOUNDS USEFUL AS DPP-IV INHIBITORS | Novartis AG (CH) | 2008-09-10 | — | — | EP | disclosed |
| WO-2007071738-A1 | CONDENSED HETEROCYCLIC COMPOUNDS USEFUL AS DPP-IV INHIBITORS | NOVARTIS AG (CH) | 2007-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192138-A1 | COMPOUNDS | DPP4, DPP3, DPP8 | DPP4 1/4885KCNH2 1859/4885FAP 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.